H.C. Wainwright Downgrades Prana Biotechnology (PRAN) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Prana Biotechnology (PRAN) Sinks as Alzheimer's Trial Fails
March 31, 2014 8:11 AM EDTPrana Biotechnology (NASDAQ: PRAN) is trading down 67% in pre-open action after the company's Phase II trail for its PBT2 did not meet its primary endpoint of a statistically significant reduction in the levels of beta-amyloid plaques in the brains of prodromal/mild Alzheimers disease patients.... More
Prana Biotech (PRAN) Reports PBT2 Phase II Did Not Meet Primary Endpoint in Alzheimer's Disease
March 31, 2014 6:15 AM EDTPrana Biotechnology (Nasdaq: PRAN) has released the top line results of the 12-month Phase II Imaging trial in Alzheimer's Disease (IMAGINE Trial), based on draft results.
Pranas PBT2 did not meet its primary endpoint of a statistically significant reduction in the levels of beta-amyloid plaques in the brains of prodromal/mild Alzheimers disease patients, as measured using PiB-PET Standardized Uptake Value Ratio (SUVR). Whilst there was a reduction in the overall levels of the PiB PET signal in patients treated with PBT2, the results were confounded by an atypical... More
